Prediction of Bleeding Risk After Anticoagulant Therapy for Atrial Fibrillation Based on Proteomics and Metabolomics
NCT ID: NCT05181774
Last Updated: 2022-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2021-12-20
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Design: AF patients treated with oral anticoagulants were enrolled in this study. Blood samples were centrifuged and the supernatant was stored in the refrigerator at - 80 ℃. All patients were followed up for one year to determine whether bleeding occurred after oral anticoagulants. Proteomic data were obtained by LC-MS/MS Analysis-DIA platform. Metabolomic data were obtained by UPLC-QTOF/MS platform. All of the omics data were used to compare proteins/enzymes with metabolic pathways. Quantitative changes of individual metabolites and proteins were calculated and graphed using the KEGG mapping tools.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers of Atrial Fibrillation Complicated With Stroke Based on Proteomics and Metabolomics
NCT05181787
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
NCT05316870
New-Onset Atrial Fibrillation Complicating Acute Myocardial Infarction in China
NCT05511649
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
NCT01706146
Investigation of Specific Biomarkers in Patients With Atrial Fibrillation Who Undergo Interventional Treatment
NCT05170607
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bleeding
After one-year follow-up, AF patients with anticoagulation-related bleeding complications were enrolled in this group.
Proteomics
Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
Metabolomics
Metabolomic data were obtained by UPLC-QTOF/MS platform.
Non-bleeding
After one-year follow-up, AF patients without anticoagulation-related bleeding complications were enrolled in this group.
Proteomics
Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
Metabolomics
Metabolomic data were obtained by UPLC-QTOF/MS platform.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Proteomics
Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
Metabolomics
Metabolomic data were obtained by UPLC-QTOF/MS platform.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Admission with atrial fibrillation or clinic visit for atrial fibrillation
3. Receive routine anticoagulant therapy;
4. Signing the consent form
Exclusion Criteria
2. Lactating women;
3. Severe mitral stenosis;
4. Severe impairment of liver function;
5. Severe renal insufficiency;
6. Thyroid dysfunction requiring treatment;
7. Have a history of severe bleeding within five years, such as intracerebral hemorrhage and gastrointestinal bleeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yue LI
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yue LI
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yan
Harbin, Heilongjiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AF and stroke 2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.